<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6901432</article-id><article-id pub-id-type="doi">10.3389/fmicb.2019.02790</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Michaelis</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/19228/overview"/></contrib><contrib contrib-type="author"><name><surname>Kleinschmidt</surname><given-names>Malte C.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/830782/overview"/></contrib><contrib contrib-type="author"><name><surname>Bojkova</surname><given-names>Denisa</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rabenau</surname><given-names>Holger F.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wass</surname><given-names>Mark N.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/104376/overview"/></contrib><contrib contrib-type="author"><name><surname>Cinatl Jr.</surname><given-names>Jindrich</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/536948/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Industrial Biotechnology Centre, School of Biosciences, University of Kent</institution>, <addr-line>Canterbury</addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><sup>2</sup><institution>Institut f&#x000fc;r Medizinische Virologie, Klinikum der Goethe-Universit&#x000e4;t</institution>, <addr-line>Frankfurt am Main</addr-line>, <country>Germany</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Michael Nevels, University of St Andrews, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: Junji Xing, Houston Methodist Research Institute, United States; Oliver H. Kr&#x000e4;mer, Johannes Gutenberg University Mainz, Germany</p></fn><corresp id="c001">*Correspondence: Jindrich Cinatl Jr., <email>Cinatl@em.uni-frankfurt.de</email></corresp><fn fn-type="other" id="fn004"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>03</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>2790</elocation-id><history><date date-type="received"><day>17</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Michaelis, Kleinschmidt, Bojkova, Rabenau, Wass and Cinatl.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Michaelis, Kleinschmidt, Bojkova, Rabenau, Wass and Cinatl</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Omeprazole was shown to improve the anti-cancer effects of the nucleoside analogue 5-fluorouracil. Here, we combined omeprazole with the antiviral nucleoside analogues ribavirin and acyclovir. Omeprazole did not affect the antiviral effects of ribavirin in non-toxic concentrations up to 80 &#x003bc;g/mL but increased the acyclovir-mediated effects on herpes simplex virus 1 and 2 (HSV-1 and -2) replication in a dose-dependent manner. Omeprazole alone reduced HSV-1 and -2 titers [but not HSV-induced formation of cytopathogenic effects (CPE)] at concentrations &#x02265;40 &#x003bc;g/mL. However, it exerted substantially stronger effects on acyclovir activity and also increased acyclovir activity at lower concentrations that did not directly interfere with HSV replication. Omeprazole 80 &#x003bc;g/mL caused a 10.8-fold (Vero cells) and 47.7-fold (HaCaT cells) decrease of the acyclovir concentrations that reduced HSV-1-induced CPE formation by 50% (IC<sub>50</sub>). In HSV-2-infected cells, omeprazole 80 &#x003bc;g/mL reduced the acyclovir IC<sub>50</sub> by 7.3- (Vero cells) and 12.9-fold (HaCaT cells). In HaCaT cells, omeprazole 80 &#x003bc;g/mL reduced the HSV-1 titer in the presence of acyclovir 1 &#x003bc;g/mL by 1.6 &#x000d7; 10<sup>5</sup>-fold and the HSV-2 titer in the presence of acyclovir 2 &#x003bc;g/mL by 9.2 &#x000d7; 10<sup>3</sup>-fold. The proton pump inhibitors pantoprazole, rabeprazole, lansoprazole, and dexlansoprazole increased the antiviral effects of acyclovir in a similar fashion as omeprazole, indicating this to be a drug class effect. In conclusion, proton pump inhibitors increase the anti-HSV activity of acyclovir and are candidates for antiviral therapies in combination with acyclovir, in particular for topical preparations for the treatment of immunocompromised individuals who are more likely to suffer from severe complications.</p></abstract><kwd-group><kwd>HSV</kwd><kwd>HSV-1</kwd><kwd>HSV-2</kwd><kwd>antiviral therapy</kwd><kwd>antiviral drugs</kwd><kwd>ribavirin</kwd><kwd>proton pump inhibitors</kwd></kwd-group><counts><fig-count count="4"/><table-count count="0"/><equation-count count="0"/><ref-count count="38"/><page-count count="7"/><word-count count="0"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Omeprazole and other proton pump inhibitors have been found to increase the activity of anti-cancer drugs including the nucleoside analogue 5-fluorouracil (<xref rid="B26" ref-type="bibr">Luciani et al., 2004</xref>; <xref rid="B15" ref-type="bibr">Ikemura et al., 2017</xref>). Proton pump inhibitors are the most frequently prescribed drugs for the treatment and prophylaxis of gastroesophageal reflux as well as of gastric and duodenal ulcers that are associated with hyper-acidic states. Since they are known to be well-tolerated, they were suggested as repositioning candidates for the use as part of anti-cancer therapies (<xref rid="B26" ref-type="bibr">Luciani et al., 2004</xref>; <xref rid="B15" ref-type="bibr">Ikemura et al., 2017</xref>).</p><p>Nucleoside analogues are also widely used as antiviral drugs (<xref rid="B6" ref-type="bibr">Chaudhuri et al., 2018</xref>; <xref rid="B7" ref-type="bibr">Chemaly et al., 2019</xref>). Here, we investigated the effects of omeprazole on the efficacy of the antiviral nucleoside analogues acyclovir and ribavirin. The guanosine analogue acyclovir and its pro-drug valacyclovir are used for the treatment of disease caused by herpes simplex virus 1 (HSV-1) and 2 (HSV-2) and varicella zoster virus (VZV) (<xref rid="B38" ref-type="bibr">Zarrouk et al., 2017</xref>). Acyclovir is activated by the viral thymidine kinase and then di- and tri-phosphorylated by cellular kinases. The active tri-phosphorylated forms of acyclovir and then specifically interferes with the viral DNA polymerase and causes chain termination (<xref rid="B32" ref-type="bibr">Piret and Boivin, 2016</xref>; <xref rid="B8" ref-type="bibr">Chen et al., 2017</xref>; <xref rid="B38" ref-type="bibr">Zarrouk et al., 2017</xref>). Ribavirin is a guanosine analogue that has been shown to exert broad-spectrum activity against RNA and DNA viruses including influenza viruses and West Nile virus. The mechanisms by which ribavirin interferes with virus replication are not clear and may be virus-dependent (<xref rid="B35" ref-type="bibr">Sidwell et al., 1972</xref>; <xref rid="B9" ref-type="bibr">Day et al., 2005</xref>; <xref rid="B4" ref-type="bibr">Beaucourt and Vignuzzi, 2014</xref>; <xref rid="B22" ref-type="bibr">Koh and Liang, 2014</xref>; <xref rid="B11" ref-type="bibr">Galli et al., 2018</xref>; <xref rid="B17" ref-type="bibr">Jordan et al., 2018</xref>; <xref rid="B20" ref-type="bibr">Keppeke et al., 2019</xref>). Our findings show that omeprazole (and other proton pump inhibitors) increase the antiviral activity of acyclovir but not that of ribavirin.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S2.SS1"><title>Cell Culture</title><p>Vero and MDCK cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, United States) and cultured at 37&#x000b0;C in minimum essential medium (MEM) supplemented with 10% fetal bovine serum. HaCaT cells were purchased from CLS Cell Line Services GmbH (Eppelheim, Germany) and cultivated in Iscove&#x02019;s modified Dulbecco&#x02019;s medium (IMDM) supplemented with 10% fetal bovine serum.</p></sec><sec id="S2.SS2"><title>Viruses</title><p>HSV-1 strain McIntyre and HSV-2 strain MS were both obtained from ATCC. West Nile virus (WNV) strain NY385-99 was kindly provided by Dr. J. ter Meulen (Institut f&#x000fc;r Virologie, Philipps-Universit&#x000e4;t, Marburg, Germany). Virus stocks were prepared in Vero cells grown in MEM with 4% fetal bovine serum. The influenza virus strain Influenza A/New Caledonia/20/99 (H1N1) was received from the WHO Influenza Centre (National Institute for Medical Research, London, United Kingdom). Virus stocks were prepared in MDCK cells grown in 4% fetal bovine serum. Infectious virus titers were determined by titration on MDCK cell monolayers in 96-well plates and expressed as 50% tissue culture infectious dose (TCID<sub>50</sub>) by the method of Spearman and K&#x000e4;rber (<xref rid="B36" ref-type="bibr">Spearman, 1908</xref>; <xref rid="B18" ref-type="bibr">K&#x000e4;rber, 1931</xref>).</p></sec><sec id="S2.SS3"><title>Drugs</title><p>Acyclovir was received from GlaxoSmithKline (Munich, Germany), omeprazole from AstraZeneca (Wedel, Germany), ribavirin from Valeant Pharmaceuticals Germany GmbH (Eschborn, Germany), and pantoprazole, rabeprazole, lansoprazole, and dexlansoprazole from Selleck Chemicals (via Absource Diagnostics GmbH, Munich, Germany).</p></sec><sec id="S2.SS4"><title>Cytopathogenic Effect (CPE) Reduction Assay</title><p>For the investigation of HSV-1- and HSV-2-induced cytopathogenic effects (CPEs), confluent Vero or HaCaT cell monolayer in 96-well microtiter plates were inoculated with HSV-1 or HSV-2 at MOI 1 or 0.1, respectively. Following a 1 h incubation period, the inoculum was removed and the drugs, either alone or in combination, were added. The virus-induced CPE was recorded microscopically after 48 h post infection.</p><p>For the investigation of WNV-induced CPEs, Vero cell monolayers were infected with MOI 0.1. Following a 1 h virus incubation period, the medium was removed and replaced by medium containing different drug concentrations. The CPE was recorded at 48 h post infection.</p><p>Confluent MDCK cell monolayers were infected with Influenza H1N1 (MOI 0.01). Following a 1 h virus incubation period, the medium was removed and infected cells were incubated in medium containing different concentrations of drugs at the respective concentration. The CPE was recorded at 24 h post infection.</p><p>Cytopathogenic effects were scored by two independent examiners and expressed in% of the untreated virus control that was defined to be 100%.</p></sec><sec id="S2.SS5"><title>Immunostaining</title><p>Intracellular HSV protein was evaluated by immunostaining. Cells were fixed with 60/40 ice cold methanol/acetone for 15 min. Staining was performed using a rabbit polyclonal antibody directed against HSV-1 (ab9533) and a sheep polyclonal antibody directed against HSV-2 (ab21112) in combination with biotin-conjugated secondary goat anti-rabbit (ab6720) and rabbit anti-sheep (ab6746) antibodies (all antibodies derived from Abcam, Cambridge, United Kingdom). Protein was visualized using streptavidin peroxidase complex with AEC as a substrate.</p></sec><sec id="S2.SS6"><title>Viability Assay</title><p>The cellular viability was assessed on confluent cell layers with the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay method as described previously (<xref rid="B28" ref-type="bibr">Michaelis et al., 2007</xref>). The viability was expressed as percentage of non-treated control.</p></sec><sec id="S2.SS7"><title>Western Blot</title><p>Cells were lysed using Triton-X-100 sample buffer, and proteins were separated by SDS-PAGE. Detection occurred by using specific antibodies against HSV-1/2 gB (10B7) (sc-56987, Santa Cruz Biotechnology, Dallas, TX, United States) and &#x003b1;-tubulin (ab4074, Abcam, Cambridge, United Kingdom). Proteins were visualized by enhanced chemiluminescence using a commercially available kit (Bio-Rad, Feldkirchen, Germany).</p></sec><sec id="S2.SS8"><title>Statistics</title><p>Results are expressed as mean &#x000b1; S.D. of at least three experiments. Comparisons between two groups were performed using Student&#x02019;s <italic>t</italic>-test. Three and more groups were compared by ANOVA followed by the Student-Newman&#x02013;Keuls test. <italic>P</italic>-values lower than 0.05 were considered to be significant.</p></sec></sec><sec id="S3"><title>Results</title><sec id="S3.SS1"><title>Effects of Omeprazole on Cell Viability</title><p>The effects of omeprazole on the viability of the investigated cell lines was tested in concentrations of up to 160 &#x003bc;g/mL. Omeprazole concentrations of 80 &#x003bc;g/mL and lower did not affect the viability of any of the tested cell lines. Omeprazole 160 &#x003bc;g/mL resulted in a reduction of cell viability, but the concentration that reduces cell viability by 50% (CC<sub>50</sub>) was not reached (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref>).</p></sec><sec id="S3.SS2"><title>Effects of Omeprazole in Combination With Ribavirin on Cytopathogenic Effect (CPE) Formation in WNV- or Influenza A H1N1-Infected Cells</title><p>Omeprazole 80 &#x003bc;g/mL did not alter the effects of ribavirin on CPE formation in WNV-infected Vero cells or H1N1-infected MDCK cells (<xref ref-type="fig" rid="F1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S1</xref>).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Cytopathogenic effect (CPE) formation and viral gene expression in the presence of antiviral nucleoside analogues and omeprazole. <bold>(A)</bold> Effects of omeprazole (80 &#x003bc;g/mL) on the concentrations of antiviral nucleoside analogues that reduce CPE formation by 50% (IC<sub>50</sub>) using West Nile virus (WNV)-infected Vero cells, influenza A H1N1-infected MDCK cells, and HSV-1- or HSV-2-infected Vero or HaCaT cells. Omeprazole alone did not reduce CPE formation. Numerical values are presented in <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S1</xref>. <bold>(B)</bold> Effects of omeprazole and acyclovir on the expression of virus proteins in HSV-1- and HSV-2-infected Vero cells. HSV-1-infected cells were treated with omeprazole 80 &#x003bc;g/mL and/or acyclovir 0.31 &#x003bc;g/mL. HSV-2-infected cells were treated with omeprazole 40 &#x003bc;g/mL and/or acyclovir 0.6 &#x003bc;g/mL. <bold>(C)</bold> HSV gB levels in HSV-1-infected Vero cells treated with omeprazole 80 &#x003bc;g/mL and/or acyclovir 0.31 &#x003bc;g/mL as determined by Western blot 24 h post infection.</p></caption><graphic xlink:href="fmicb-10-02790-g001"/></fig></sec><sec id="S3.SS3"><title>Effects of Omeprazole in Combination With Acyclovir on HSV-1 and HSV-2 Replication</title><p>HSV-1- and HSV-2-induced CPE formation were investigated in Vero and HaCaT cells. Vero is a continuous cell line derived from kidney epithelial cells of an African green monkey (<xref rid="B37" ref-type="bibr">Yasumura and Kawakita, 1963</xref>). Vero cells are interferon-deficient and used to cultivate many different viruses (<xref rid="B10" ref-type="bibr">Desmyter et al., 1968</xref>; <xref rid="B29" ref-type="bibr">Montagnon and Vincent-Falquet, 1998</xref>; <xref rid="B3" ref-type="bibr">Barrett et al., 2009</xref>). HaCaT is a spontaneously immortalized human keratinocyte cell line (<xref rid="B5" ref-type="bibr">Boukamp et al., 1988</xref>). Omeprazole on its own did not affect HSV-1- and HSV-2-induced CPE formation (<xref ref-type="supplementary-material" rid="SM2">Supplementary Table S1</xref>). In the presence of omeprazole 80 &#x003bc;g/mL, however, acyclovir concentrations that reduced CPE formation by 50% (IC<sub>50</sub>) were reduced by 11-fold in HSV-1-infected Vero cells and by 7-fold in HSV-2-infected Vero cells (<xref ref-type="fig" rid="F1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S1</xref>). Further, omeprazole 80 &#x003bc;g/mL reduced the acyclovir IC<sub>50</sub>s by 48-fold in HSV-1-infected HaCaT cells and by 13-fold in HSV-2-infected HaCaT cells (<xref ref-type="fig" rid="F1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="SM2">Supplementary Table S1</xref>). Immune staining also indicated reduced numbers of virus-infected cells after treatment with a combination of omeprazole and acyclovir compared to either single treatment (<xref ref-type="fig" rid="F1">Figure 1B</xref>). In agreement, Western blot analysis demonstrated strongly reduced HSV gB protein levels in cells treated with this combination (<xref ref-type="fig" rid="F1">Figure 1C</xref>). Further experiments indicated that omeprazole reduced acyclovir IC<sub>50</sub>s in HSV-1- and HSV-2-infected HaCaT cells in a dose-dependent fashion (<xref ref-type="fig" rid="F2">Figure 2</xref> and <xref ref-type="supplementary-material" rid="SM3">Supplementary Table S2</xref>).</p><fig id="F2" position="float"><label>FIGURE 2</label><caption><p>Concentration-dependent effects of omeprazole on the acyclovir IC<sub>50</sub> in HSV-1- or HSV-2-infected HaCaT cells as determined by cytopathogenic effect (CPE) formation. Numerical values are presented in <xref ref-type="supplementary-material" rid="SM3">Supplementary Table S2</xref>. The investigated drug concentrations did not affect cell viability, neither alone or in combination. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 relative to nucleoside analogue alone.</p></caption><graphic xlink:href="fmicb-10-02790-g002"/></fig><p>Although omeprazole did not affect the HSV-1 and HSV-2 CPEs in concentrations of up to 80 &#x003bc;g/mL, the determination of virus titers in Vero cells showed that 80 &#x003bc;g/mL omeprazole inhibited the production of infectious HSV-1 particles and that 40 and 80 &#x003bc;g/mL omeprazole inhibited the production of infectious HSV-2 particles. In agreement with the findings from the CPE assays, omeprazole also strongly increased the anti-HSV-1 and anti-HSV-2 effects of acyclovir. Notably, this omeprazole-induced increase of acyclovir activity was also seen at lower omeprazole concentrations, which did not directly reduce virus titers (<xref ref-type="fig" rid="F3">Figure 3</xref> and <xref ref-type="supplementary-material" rid="SM4">Supplementary Table S3</xref>). The investigated omeprazole and acyclovir concentrations did not affect cell viability, neither alone not in combination.</p><fig id="F3" position="float"><label>FIGURE 3</label><caption><p>Effect of acyclovir 1 &#x003bc;g/mL (HSV-1) or 2 &#x003bc;g/mL (HSV-2) alone or in combination with varying omeprazole (OME) concentrations (&#x003bc;g/mL) on HSV-1 and HSV-2 titres in HaCaT cells. Numerical values are presented in <xref ref-type="supplementary-material" rid="SM4">Supplementary Table S3</xref>. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 relative to acyclovir alone, <sup>#</sup><italic>P</italic> &#x0003c; 0.05 relative to untreated virus control; N.D. = no detectable virus titre.</p></caption><graphic xlink:href="fmicb-10-02790-g003"/></fig></sec><sec id="S3.SS4"><title>Effects of Various Proton Pump Inhibitors on HSV-1-Induced Cytopathogenic Effects (CPEs)</title><p>Finally, we tested the effects of the additional proton pump inhibitors pantoprazole, rabeprazole, lansoprazole, and dexlansoprazole (<xref rid="B25" ref-type="bibr">Li et al., 2017</xref>) on CPE formation in HSV-1-infected HaCaT cells. All tested proton pump inhibitors increased the activity of acyclovir (<xref ref-type="fig" rid="F4">Figure 4</xref> and <xref ref-type="supplementary-material" rid="SM5">Supplementary Table S4</xref>), which suggests that this is a drug class effect.</p><fig id="F4" position="float"><label>FIGURE 4</label><caption><p>Effects of different proton pump inhibitors on acyclovir activity in HSV-1-infected HaCaT cells as indicated by cytopathogenic effect (CPE) formation. Proton pump inhibitors alone did not reduce CPE formation. Numerical values are presented in <xref ref-type="supplementary-material" rid="SM5">Supplementary Table S4</xref>. <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 relative to acyclovir alone.</p></caption><graphic xlink:href="fmicb-10-02790-g004"/></fig></sec></sec><sec id="S4"><title>Discussion</title><p>Based on previous investigations that showed that omeprazole increases the anti-cancer activity of the nucleoside analog 5-fluorouracil (<xref rid="B26" ref-type="bibr">Luciani et al., 2004</xref>), we here investigated the effects of omeprazole on the antiviral effects of ribavirin and acyclovir. Omeprazole did not modify ribavirin-mediated effects in H1N1 influenza A virus-infected or West Nile virus-infected cell cultures but increased the efficacy of acyclovir, a first line drug for HSV-1, HSV-2, and varicella zoster virus infection (<xref rid="B32" ref-type="bibr">Piret and Boivin, 2016</xref>; <xref rid="B21" ref-type="bibr">Klysik et al., 2018</xref>), in a dose-dependent fashion in Vero and HaCaT cells. It remains unclear why omeprazole increases the activity of acyclovir but not that of ribavirin. Differences between the compounds acyclovir and ribavirin including their mechanisms of action and/or differences between the investigated viruses may be responsible for this.</p><p>The mechanism by which omeprazole enhances the activity of acyclovir seems to differ from the mechanism by which omeprazole increases 5-fluorouracil efficacy, which was shown to be the consequence of an increase of the lysosomal pH (<xref rid="B26" ref-type="bibr">Luciani et al., 2004</xref>). Lysosomotropic drugs such as chloroquine and ammonium chloride are known to interfere with the infection of viruses including HSV. These drugs increase intracellular pH presumably resulting in inhibition of viral packing and maturation through <italic>trans</italic>-Golgi network, although their exact mechanisms of antiviral activity remain unclear (<xref rid="B23" ref-type="bibr">Koyama and Uchida, 1984</xref>, <xref rid="B24" ref-type="bibr">1989</xref>; <xref rid="B16" ref-type="bibr">Johnson and Baines, 2011</xref>; <xref rid="B1" ref-type="bibr">Al-Bari, 2017</xref>; <xref rid="B33" ref-type="bibr">Salata et al., 2017</xref>). In agreement, omeprazole concentrations &#x02265;40 &#x003bc;g/mL reduced HSV-1 and HSV-2 titers. However, the effects of omeprazole on the anti-HSV activity of acyclovir were more pronounced than the direct antiviral effects and lower omeprazole concentrations, which did not affect HSV-1 and HSV-2 replication, still substantially enhanced the efficacy of acyclovir. This indicates that the induction of increased acyclovir activity is not a direct consequence of antiviral activity exerted by omeprazole and may be caused by a different mechanism. Moreover, omeprazole pre-treatment was necessary to increase 5-fluorouracil activity (<xref rid="B26" ref-type="bibr">Luciani et al., 2004</xref>), but omeprazole and acyclovir exerted their combined activity when added at the same time 1 h post infection. This indicates that the mechanisms by which omeprazole increases 5-fluorouracil and acyclovir activity differ and that omeprazole increases the antiviral activity of acyclovir during the viral replication cycle after infection and virus internalization. The proton pump inhibitors pantoprazole, rabeprazole, lansoprazole, and dexlansoprazole increased acyclovir activity in a similar manner as omeprazole. Hence, the capacity to increase the antiviral activity of acyclovir seems to be a drug class effect, which is common to proton pump inhibitors in general. Notably, proton pump inhibitors have been shown to exert anti-inflammatory and antioxidative effects independently of their effects on H<sup>+</sup>/K<sup>+</sup> ATPase activity, which may contribute to the increased acyclovir activity mediated by proton pump inhibitors (<xref rid="B2" ref-type="bibr">Balza et al., 2016</xref>; <xref rid="B30" ref-type="bibr">Nelson et al., 2017</xref>; <xref rid="B12" ref-type="bibr">Ghebre, 2018</xref>). In addition, omeprazole may inhibit DNA damage repair (<xref rid="B27" ref-type="bibr">Martelli et al., 1998</xref>), which may increase the efficacy of acyclovir. Therefore, proton pump inhibitors may increase acyclovir activity by mechanisms that do not involve the modulation of the lysosomal pH.</p><p>Since omeprazole is a clinically well-established drug with a preferable safety profile, it is an excellent candidate for drug repositioning strategies (<xref rid="B15" ref-type="bibr">Ikemura et al., 2017</xref>), and there is a need for improved therapies for HSV-1- and HSV-2-associated disease. After primary infection, HSV-1 and HSV-2 establish life-long persistence which may result in recurrent disease which typically manifests as herpes labialis or herpes genitalis and which may be associated with significant morbidity (<xref rid="B13" ref-type="bibr">Gnann and Whitley, 2016</xref>; <xref rid="B14" ref-type="bibr">Heslop et al., 2016</xref>; <xref rid="B21" ref-type="bibr">Klysik et al., 2018</xref>). Even in the case of herpes labialis, which is not commonly associated with severe complications, treatment success is not always satisfactory as highlighted by the introduction of topical acyclovir/hydrocortisone combinations (<xref rid="B31" ref-type="bibr">Nguyen et al., 2014</xref>). Omeprazole may not exert general immunosuppressive effects in the same way as hydrocortisone but to more specifically increase acyclovir activity. In immunodeficiency individuals, HSV-1 and -2 infections are often associated with more severe disease, and resistance formation to acyclovir is a severe problem (<xref rid="B32" ref-type="bibr">Piret and Boivin, 2016</xref>; <xref rid="B19" ref-type="bibr">Karrasch et al., 2018</xref>). Moreover, ocular HSV infection is a major cause of blindness in industrialized countries (<xref rid="B21" ref-type="bibr">Klysik et al., 2018</xref>). Thus, more effective treatment options for HSV-1- and HSV-2-caused disease are highly desirable. In this context, proton pump inhibitors are promising candidates for combination with acyclovir or valacyclovir in topical preparations. Further research will have to show to which extent effective proton pump inhibitor concentrations can also be achieved systemically. For omeprazole, maximum plasma levels have been described to reach about 8 &#x003bc;g/mL, when it is used for inhibition of acid secretion in the stomach (<xref rid="B34" ref-type="bibr">Shin and Kim, 2013</xref>). Hence, the achievement of therapeutically effective plasma concentrations seems possible, given that a dose increase may be feasible in a severe acute disease setting.</p><p>In conclusion, omeprazole and other proton pump inhibitors substantially enhance the antiviral effects of acyclovir in HSV-1- and HSV-2-infected cells. With their known safety profiles, proton pump inhibitors are promising candidates for drug repurposing approaches (<xref rid="B15" ref-type="bibr">Ikemura et al., 2017</xref>), in particular for topical preparations.</p></sec><sec sec-type="data-availability" id="S5"><title>Data Availability Statement</title><p>All datasets for this study are included in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>.</p></sec><sec id="S6"><title>Author Contributions</title><p>MM and JC designed and conducted the study. MK, DB, and JC performed experiments. All authors analyzed and curated data. MM and JC wrote the initial manuscript draft. All authors read, revised, and approved the final version of the manuscript.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> The work was supported by the Hilfe f&#x000fc;r krebskranke Kinder Frankfurt e.V. and the Frankfurter Stiftung f&#x000fc;r krebskranke Kinder.</p></fn></fn-group><ack><p>The authors thank Gesa Meincke for technical support. A version of this manuscript has been released as a Pre-Print at bioRxiv (doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/313072">https://doi.org/10.1101/313072</ext-link>).</p></ack><sec id="S9" sec-type="supplementary material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmicb.2019.02790/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmicb.2019.02790/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Data_Sheet_1.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><media xlink:href="Data_Sheet_2.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM3"><media xlink:href="Data_Sheet_3.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM4"><media xlink:href="Data_Sheet_4.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM5"><media xlink:href="Data_Sheet_5.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Bari</surname><given-names>M. A. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.</article-title>
<source><italic>Pharmacol. Res. Perspect.</italic></source>
<volume>5</volume>:<issue>e00293</issue>. <pub-id pub-id-type="doi">10.1002/prp2.293</pub-id>
<?supplied-pmid 28596841?><pub-id pub-id-type="pmid">28596841</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balza</surname><given-names>E.</given-names></name><name><surname>Piccioli</surname><given-names>P.</given-names></name><name><surname>Carta</surname><given-names>S.</given-names></name><name><surname>Lavieri</surname><given-names>R.</given-names></name><name><surname>Gattorno</surname><given-names>M.</given-names></name><name><surname>Semino</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance.</article-title>
<source><italic>Cell Death Dis.</italic></source>
<volume>7</volume>:<issue>e2304</issue>. <pub-id pub-id-type="doi">10.1038/cddis.2016.218</pub-id>
<?supplied-pmid 27441656?><pub-id pub-id-type="pmid">27441656</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>P. N.</given-names></name><name><surname>Mundt</surname><given-names>W.</given-names></name><name><surname>Kistner</surname><given-names>O.</given-names></name><name><surname>Howard</surname><given-names>M. K.</given-names></name></person-group> (<year>2009</year>). <article-title>Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.</article-title>
<source><italic>Expert Rev. Vaccines.</italic></source>
<volume>8</volume>
<fpage>607</fpage>&#x02013;<lpage>618</lpage>. <pub-id pub-id-type="doi">10.1586/erv.09.19</pub-id>
<?supplied-pmid 19397417?><pub-id pub-id-type="pmid">19397417</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaucourt</surname><given-names>S.</given-names></name><name><surname>Vignuzzi</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance.</article-title>
<source><italic>Curr. Opin. Virol.</italic></source>
<volume>8</volume>
<fpage>10</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2014.04.011</pub-id>
<?supplied-pmid 24846716?><pub-id pub-id-type="pmid">24846716</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boukamp</surname><given-names>P.</given-names></name><name><surname>Petrussevska</surname><given-names>R. T.</given-names></name><name><surname>Breitkreutz</surname><given-names>D.</given-names></name><name><surname>Hornung</surname><given-names>J.</given-names></name><name><surname>Markham</surname><given-names>A.</given-names></name><name><surname>Fusenig</surname><given-names>N. E.</given-names></name></person-group> (<year>1988</year>). <article-title>Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line.</article-title>
<source><italic>J. Cell Biol.</italic></source>
<volume>106</volume>
<fpage>761</fpage>&#x02013;<lpage>771</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.106.3.761</pub-id>
<?supplied-pmid 2450098?><pub-id pub-id-type="pmid">2450098</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>S.</given-names></name><name><surname>Symons</surname><given-names>J. A.</given-names></name><name><surname>Deval</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>155</volume>
<fpage>76</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.05.005</pub-id>
<?supplied-pmid 29758235?><pub-id pub-id-type="pmid">29758235</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chemaly</surname><given-names>R. F.</given-names></name><name><surname>Hill</surname><given-names>J. A.</given-names></name><name><surname>Voigt</surname><given-names>S.</given-names></name><name><surname>Peggs</surname><given-names>K. S.</given-names></name></person-group> (<year>2019</year>). <article-title>In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>163</volume>
<fpage>50</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2019.01.008</pub-id>
<?supplied-pmid 30677427?><pub-id pub-id-type="pmid">30677427</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Efficacy and safety of nucleoside antiviral drugs for treatment of recurrent herpes labialis: a systematic review and meta-analysis.</article-title>
<source><italic>J. Oral. Pathol. Med.</italic></source>
<volume>46</volume>
<fpage>561</fpage>&#x02013;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1111/jop.12534</pub-id>
<?supplied-pmid 27935123?><pub-id pub-id-type="pmid">27935123</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>C. W.</given-names></name><name><surname>Smee</surname><given-names>D. F.</given-names></name><name><surname>Julander</surname><given-names>J. G.</given-names></name><name><surname>Yamshchikov</surname><given-names>V. F.</given-names></name><name><surname>Sidwell</surname><given-names>R. W.</given-names></name><name><surname>Morrey</surname><given-names>J. D.</given-names></name></person-group> (<year>2005</year>). <article-title>Error-prone replication of West Nile virus caused by ribavirin.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>67</volume>
<fpage>38</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2005.04.002</pub-id>
<?supplied-pmid 15919121?><pub-id pub-id-type="pmid">15919121</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmyter</surname><given-names>J.</given-names></name><name><surname>Melnick</surname><given-names>J. L.</given-names></name><name><surname>Rawls</surname><given-names>W. E.</given-names></name></person-group> (<year>1968</year>). <article-title>Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero).</article-title>
<source><italic>J. Virol.</italic></source>
<volume>2</volume>
<fpage>955</fpage>&#x02013;<lpage>961</lpage>. <?supplied-pmid 4302013?><pub-id pub-id-type="pmid">4302013</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>A.</given-names></name><name><surname>Mens</surname><given-names>H.</given-names></name><name><surname>Gottwein</surname><given-names>J. M.</given-names></name><name><surname>Gerstoft</surname><given-names>J.</given-names></name><name><surname>Bukh</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Antiviral effect of Ribavirin against HCV associated with increased frequency of G-to-A and C-to-U transitions in infectious cell culture model.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>8</volume>:<issue>4619</issue>. <pub-id pub-id-type="doi">10.1038/s41598-018-22620-22622</pub-id>
<?supplied-pmid 29545599?><pub-id pub-id-type="pmid">29545599</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghebre</surname><given-names>Y. T.</given-names></name></person-group> (<year>2018</year>). <article-title>Proton pump inhibitors in IPF: a call for clinical trials.</article-title>
<source><italic>Front. Pharmacol.</italic></source>
<volume>9</volume>:<issue>499</issue>. <pub-id pub-id-type="doi">10.3389/fphar.2018.00499</pub-id>
<?supplied-pmid 29867501?><pub-id pub-id-type="pmid">29867501</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnann</surname><given-names>J. W.</given-names><suffix>Jr.</suffix></name><name><surname>Whitley</surname><given-names>R. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Clinical practice.</article-title>
<source><italic>Genital. Herpes. N. Engl. J. Med.</italic></source>
<volume>375</volume>
<fpage>666</fpage>&#x02013;<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMcp1603178</pub-id>
<?supplied-pmid 27532832?><pub-id pub-id-type="pmid">27532832</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heslop</surname><given-names>R.</given-names></name><name><surname>Roberts</surname><given-names>H.</given-names></name><name><surname>Flower</surname><given-names>D.</given-names></name><name><surname>Jordan</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Interventions for men and women with their first episode of genital herpes.</article-title>
<source><italic>Cochrane Database Syst. Rev.</italic></source>
<volume>8</volume>:<issue>CD010684</issue>. <pub-id pub-id-type="doi">10.1002/14651858.CD010684.pub2</pub-id>
<?supplied-pmid 28120659?><pub-id pub-id-type="pmid">28120659</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikemura</surname><given-names>K.</given-names></name><name><surname>Hiramatsu</surname><given-names>S.</given-names></name><name><surname>Okuda</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Drug repositioning of proton pump inhibitors for enhanced efficacy and safety of cancer chemotherapy.</article-title>
<source><italic>Front. Pharmacol.</italic></source>
<volume>8</volume>:<issue>911</issue>. <pub-id pub-id-type="doi">10.3389/fphar.2017.00911</pub-id>
<?supplied-pmid 29311921?><pub-id pub-id-type="pmid">29311921</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D. C.</given-names></name><name><surname>Baines</surname><given-names>J. D.</given-names></name></person-group> (<year>2011</year>). <article-title>Herpesviruses remodel host membranes for virus egress.</article-title>
<source><italic>Nat. Rev. Microbiol.</italic></source>
<volume>9</volume>
<fpage>382</fpage>&#x02013;<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2559</pub-id>
<?supplied-pmid 21494278?><pub-id pub-id-type="pmid">21494278</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>P. C.</given-names></name><name><surname>Stevens</surname><given-names>S. K.</given-names></name><name><surname>Deval</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Nucleosides for the treatment of respiratory RNA virus infections.</article-title>
<source><italic>Antivir. Chem. Chemother.</italic></source>
<volume>26</volume>:<issue>2040206618764483</issue>. <pub-id pub-id-type="doi">10.1177/2040206618764483</pub-id>
<?supplied-pmid 29562753?><pub-id pub-id-type="pmid">29562753</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000e4;rber</surname><given-names>G.</given-names></name></person-group> (<year>1931</year>). <article-title>Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche [A contribution to the collective treatment of a pharmacological experimental series].</article-title>
<source><italic>Archiv. f&#x000fc;r Experimentelle Pathologie und Pharmakologie</italic></source>
<volume>162</volume>
<fpage>480</fpage>&#x02013;<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1007/bf01863914</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karrasch</surname><given-names>M.</given-names></name><name><surname>Liermann</surname><given-names>K.</given-names></name><name><surname>Betz</surname><given-names>B. B.</given-names></name><name><surname>Wagner</surname><given-names>S.</given-names></name><name><surname>Scholl</surname><given-names>S.</given-names></name><name><surname>Dahms</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Rapid acquisition of acyclovir resistance in an immunodeficient patient with herpes simplex encephalitis.</article-title>
<source><italic>J. Neurol. Sci.</italic></source>
<volume>384</volume>
<fpage>89</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2017.11.024</pub-id>
<?supplied-pmid 29249385?><pub-id pub-id-type="pmid">29249385</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keppeke</surname><given-names>G. D.</given-names></name><name><surname>Calise</surname><given-names>S. J.</given-names></name><name><surname>Chan</surname><given-names>E. K. L.</given-names></name><name><surname>Andrade</surname><given-names>L. E. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Ribavirin induces widespread accumulation of IMP dehydrogenase into rods/rings structures in multiple major mouse organs.</article-title>
<source><italic>Antiviral. Res.</italic></source>
<volume>162</volume>
<fpage>130</fpage>&#x02013;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.12.017</pub-id>
<?supplied-pmid 30605724?><pub-id pub-id-type="pmid">30605724</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klysik</surname><given-names>K.</given-names></name><name><surname>Pietraszek</surname><given-names>A.</given-names></name><name><surname>Karewicz</surname><given-names>A.</given-names></name><name><surname>Nowakowska</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Acyclovir in the treatment of Herpes viruses - a review.</article-title>
<source><italic>Curr. Med. Chem.</italic></source>
<comment>[Epub ahead of print]</comment>.</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>C.</given-names></name><name><surname>Liang</surname><given-names>T. J.</given-names></name></person-group> (<year>2014</year>). <article-title>What is the future of ribavirin therapy for hepatitis C?</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>104</volume>
<fpage>34</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2014.01.005</pub-id>
<?supplied-pmid 24468277?><pub-id pub-id-type="pmid">24468277</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>A. H.</given-names></name><name><surname>Uchida</surname><given-names>T.</given-names></name></person-group> (<year>1984</year>). <article-title>Inhibition of multiplication of herpes simplex virus type 1 by ammonium chloride and chloroquine.</article-title>
<source><italic>Virology</italic></source>
<volume>138</volume>
<fpage>332</fpage>&#x02013;<lpage>335</lpage>. <pub-id pub-id-type="doi">10.1016/0042-6822(84)90356-8</pub-id>
<?supplied-pmid 6093369?><pub-id pub-id-type="pmid">6093369</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>A. H.</given-names></name><name><surname>Uchida</surname><given-names>T.</given-names></name></person-group> (<year>1989</year>). <article-title>The effect of ammonium chloride on the multiplication of herpes simplex virus type 1 in Vero cells.</article-title>
<source><italic>Virus Res.</italic></source>
<volume>13</volume>
<fpage>271</fpage>&#x02013;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1016/0168-1702(89)90073-7</pub-id>
<?supplied-pmid 2554609?><pub-id pub-id-type="pmid">2554609</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M. J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>L. Q.</given-names></name></person-group> (<year>2017</year>). <article-title>Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: a PRISMA-compliant network meta-analysis.</article-title>
<source><italic>Medicine</italic></source>
<volume>96</volume>:<issue>e8120</issue>. <pub-id pub-id-type="doi">10.1097/MD.0000000000008120</pub-id>
<?supplied-pmid 28953640?><pub-id pub-id-type="pmid">28953640</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luciani</surname><given-names>F.</given-names></name><name><surname>Spada</surname><given-names>M.</given-names></name><name><surname>De Milito</surname><given-names>A.</given-names></name><name><surname>Molinari</surname><given-names>A.</given-names></name><name><surname>Rivoltini</surname><given-names>L.</given-names></name><name><surname>Montinaro</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.</article-title>
<source><italic>J. Natl. Cancer Inst.</italic></source>
<volume>96</volume>
<fpage>1702</fpage>&#x02013;<lpage>1713</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djh305</pub-id>
<?supplied-pmid 15547183?><pub-id pub-id-type="pmid">15547183</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martelli</surname><given-names>A.</given-names></name><name><surname>Mattioli</surname><given-names>F.</given-names></name><name><surname>Mereto</surname><given-names>E.</given-names></name><name><surname>Brambilla Campart</surname><given-names>G.</given-names></name><name><surname>Sini</surname><given-names>D.</given-names></name><name><surname>Bergamaschi</surname><given-names>G.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>Evaluation of omeprazole genotoxicity in a battery of in vitro and in vivo assays.</article-title>
<source><italic>Toxicology</italic></source>
<volume>130</volume>
<fpage>29</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/s0300-483x(98)00101-2</pub-id>
<?supplied-pmid 9846994?><pub-id pub-id-type="pmid">9846994</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaelis</surname><given-names>M.</given-names></name><name><surname>Kleinschmidt</surname><given-names>M. C.</given-names></name><name><surname>Doerr</surname><given-names>H. W.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2007</year>). <article-title>Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells.</article-title>
<source><italic>J. Antimicrob. Chemother.</italic></source>
<volume>60</volume>
<fpage>981</fpage>&#x02013;<lpage>986</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkm307</pub-id>
<?supplied-pmid 17872917?><pub-id pub-id-type="pmid">17872917</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagnon</surname><given-names>B. J.</given-names></name><name><surname>Vincent-Falquet</surname><given-names>J. C.</given-names></name></person-group> (<year>1998</year>). <article-title>Experience with the Vero cell line.</article-title>
<source><italic>Dev. Biol. Stand.</italic></source>
<volume>93</volume>
<fpage>119</fpage>&#x02013;<lpage>123</lpage>. <?supplied-pmid 9737386?><pub-id pub-id-type="pmid">9737386</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Ko</surname><given-names>K.</given-names></name><name><surname>Sikora</surname><given-names>A. G.</given-names></name><name><surname>Bonnen</surname><given-names>M. D.</given-names></name><name><surname>Enkhbaatar</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Therapeutic efficacy of Esomeprazole in cotton smoke-induced lung injury model.</article-title>
<source><italic>Front. Pharmacol.</italic></source>
<volume>8</volume>:<issue>16</issue>. <pub-id pub-id-type="doi">10.3389/fphar.2017.00016</pub-id>
<?supplied-pmid 28184197?><pub-id pub-id-type="pmid">28184197</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>H. P.</given-names></name><name><surname>Stiegel</surname><given-names>K. R.</given-names></name><name><surname>Downing</surname><given-names>C.</given-names></name><name><surname>Stiegel</surname><given-names>K. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Recent approval of Xerese in Canada: 5% acyclovir and 1% hydrocortisone topical cream in the treatment of herpes labialis.</article-title>
<source><italic>Skin Therapy Lett.</italic></source>
<volume>19</volume>
<fpage>5</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 25188362?><pub-id pub-id-type="pmid">25188362</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piret</surname><given-names>J.</given-names></name><name><surname>Boivin</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management.</article-title>
<source><italic>Curr. Opin. Infect. Dis.</italic></source>
<volume>29</volume>
<fpage>654</fpage>&#x02013;<lpage>662</lpage>. <pub-id pub-id-type="doi">10.1097/qco.0000000000000288</pub-id>
<?supplied-pmid 27306564?><pub-id pub-id-type="pmid">27306564</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salata</surname><given-names>C.</given-names></name><name><surname>Calistri</surname><given-names>A.</given-names></name><name><surname>Parolin</surname><given-names>C.</given-names></name><name><surname>Baritussio</surname><given-names>A.</given-names></name><name><surname>Pal&#x000f9;</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Antiviral activity of cationic amphiphilic drugs.</article-title>
<source><italic>Expert Rev. Anti Infect. Ther.</italic></source>
<volume>15</volume>
<fpage>483</fpage>&#x02013;<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1080/14787210.2017.1305888</pub-id>
<?supplied-pmid 28286997?><pub-id pub-id-type="pmid">28286997</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>J. M.</given-names></name><name><surname>Kim</surname><given-names>N.</given-names></name></person-group> (<year>2013</year>). <article-title>Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.</article-title>
<source><italic>J. Neurogastroenterol. Motil.</italic></source>
<volume>19</volume>
<fpage>25</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.5056/jnm.2013.19.1.25</pub-id>
<?supplied-pmid 23350044?><pub-id pub-id-type="pmid">23350044</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidwell</surname><given-names>R. W.</given-names></name><name><surname>Huffman</surname><given-names>J. H.</given-names></name><name><surname>Khare</surname><given-names>G. P.</given-names></name><name><surname>Allen</surname><given-names>L. B.</given-names></name><name><surname>Witkowski</surname><given-names>J. T.</given-names></name><name><surname>Robins</surname><given-names>R. K.</given-names></name></person-group> (<year>1972</year>). <article-title>Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.</article-title>
<source><italic>Science</italic></source>
<volume>177</volume>
<fpage>705</fpage>&#x02013;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1126/science.177.4050.705</pub-id>
<?supplied-pmid 4340949?><pub-id pub-id-type="pmid">4340949</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spearman</surname><given-names>C.</given-names></name></person-group> (<year>1908</year>). <article-title>The method of &#x0201c;right and wrong cases&#x0201d; (&#x0201c;constantstimuli&#x0201d;) without Gauss&#x02019;s formulae.</article-title>
<source><italic>Br. J. Psychol.</italic></source>
<volume>2</volume>
<fpage>227</fpage>&#x02013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1111/j.2044-8295.1908.tb00176.x</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasumura</surname><given-names>Y.</given-names></name><name><surname>Kawakita</surname><given-names>Y.</given-names></name></person-group> (<year>1963</year>). <article-title>Studies on SV40 in tissue culture-preliminary step for cancer research in vitro.</article-title>
<source><italic>Nihon Rinsho</italic></source>
<volume>21</volume>
<fpage>1201</fpage>&#x02013;<lpage>1215</lpage>.</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarrouk</surname><given-names>K.</given-names></name><name><surname>Piret</surname><given-names>J.</given-names></name><name><surname>Boivin</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Herpesvirus DNA polymerases: structures, functions and inhibitors.</article-title>
<source><italic>Virus Res.</italic></source>
<volume>234</volume>
<fpage>177</fpage>&#x02013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2017.01.019</pub-id>
<?supplied-pmid 28153606?><pub-id pub-id-type="pmid">28153606</pub-id></mixed-citation></ref></ref-list></back></article>